These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 37058230)

  • 1. Characterization of a novel tetravalent botulism antitoxin based on receptor-binding domain of BoNTs.
    Shi DY; Lu JS; Mao YY; Liu FJ; Wang R; Du P; Yu S; Yu YZ; Yang ZX
    Appl Microbiol Biotechnol; 2023 May; 107(10):3205-3216. PubMed ID: 37058230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and preclinical evaluation of a new F(ab')₂ antitoxin against botulinum neurotoxin serotype A.
    Yu YZ; Zhang SM; Wang WB; Du Y; Zhu HQ; Wang RL; Zhou XW; Lin JB; Wang S; Yu WY; Huang PT; Sun ZW
    Biochimie; 2010 Oct; 92(10):1315-20. PubMed ID: 20600570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and evaluation of candidate subunit vaccine and novel antitoxin against botulinum neurotoxin serotype E.
    Shi DY; Liu FJ; Mao YY; Cui RT; Lu JS; Yu YZ; Dong XJ; Yang ZX; Sun ZW; Pang XB
    Hum Vaccin Immunother; 2020; 16(1):100-108. PubMed ID: 31210561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F.
    Yu YZ; Zhang SM; Ma Y; Zhu HQ; Wang WB; Du Y; Zhou XW; Wang RL; Wang S; Yu WY; Huang PT; Sun ZW
    Clin Immunol; 2010 Nov; 137(2):271-80. PubMed ID: 20696619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with antitoxin antibodies from three host species.
    Atassi MZ; Dolimbek BZ; Hayakari M; Middlebrook JL; Whitney B; Oshima M
    J Protein Chem; 1996 Oct; 15(7):691-700. PubMed ID: 8968960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D.
    Moreira C; da Cunha CE; Moreira GM; Mendonça M; Salvarani FM; Moreira ÂN; Conceição FR
    Anaerobe; 2016 Aug; 40():58-62. PubMed ID: 27236078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of an Equine Antitoxin by Immunizing the Halla Horse with the Receptor-Binding Domain of Botulinum Neurotoxin Type A1.
    Kim NY; Park KE; Lee YJ; Kim YM; Hong SH; Son WR; Hong S; Lee S; Ahn HB; Yang J; Seo JP; Lim YK; Yu CH; Hur GH; Jeong ST; Lee HS; Song K; Kang TJ; Shin YK; Choi JS; Choi JY
    J Microbiol Biotechnol; 2019 Jul; 29(7):1165-1176. PubMed ID: 31280529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunologic and Protective Properties of Subunit- vs. Whole Toxoid-Derived Anti-Botulinum Equine Antitoxin.
    Ben David A; Barnea A; Torgeman A; Diamant E; Dor E; Schwartz A; Rosen O; Caspi N; Saraf M; Lerer E; Adar Y; Lupo E; Toister E; Zichel R
    Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purification and Characterization of Botulinum Neurotoxin FA from a Genetically Modified Clostridium botulinum Strain.
    Pellett S; Tepp WH; Bradshaw M; Kalb SR; Dykes JK; Lin G; Nawrocki EM; Pier CL; Barr JR; Maslanka SE; Johnson EA
    mSphere; 2016; 1(1):. PubMed ID: 27303710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing toxin-based vaccines against botulism.
    Przedpelski A; Tepp WH; Zuverink M; Johnson EA; Pellet S; Barbieri JT
    Vaccine; 2018 Feb; 36(6):827-832. PubMed ID: 29307477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subunit vaccine against the seven serotypes of botulism.
    Baldwin MR; Tepp WH; Przedpelski A; Pier CL; Bradshaw M; Johnson EA; Barbieri JT
    Infect Immun; 2008 Mar; 76(3):1314-8. PubMed ID: 18070903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H.
    Fan Y; Barash JR; Lou J; Conrad F; Marks JD; Arnon SS
    J Infect Dis; 2016 May; 213(10):1606-14. PubMed ID: 26936913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D.
    Gil LA; da Cunha CE; Moreira GM; Salvarani FM; Assis RA; Lobato FC; Mendonça M; Dellagostin OA; Conceição FR
    PLoS One; 2013; 8(7):e69692. PubMed ID: 23936080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent tetravalent replicon vaccines against botulinum neurotoxins using DNA-based Semliki Forest virus replicon vectors.
    Yu YZ; Guo JP; An HJ; Zhang SM; Wang S; Yu WY; Sun ZW
    Vaccine; 2013 May; 31(20):2427-32. PubMed ID: 23583890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pentavalent replicon vaccines against botulinum neurotoxins and tetanus toxin using DNA-based Semliki Forest virus replicon vectors.
    Yu YZ; Liu S; Ma Y; Gong ZW; Wang S; Sun ZW
    Hum Vaccin Immunother; 2014; 10(7):1874-9. PubMed ID: 25424795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation of egg yolk antibodies against BoNT/B and their passive protection in mouse models.
    You Z; Yang H; Xin W; Kang L; Gao S; Wang J; Zhang T; Wang J
    Hum Vaccin Immunother; 2014; 10(8):2321-7. PubMed ID: 25424938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Light Chain Defines the Duration of Action of Botulinum Toxin Serotype A Subtypes.
    Pellett S; Bradshaw M; Tepp WH; Pier CL; Whitemarsh RCM; Chen C; Barbieri JT; Johnson EA
    mBio; 2018 Mar; 9(2):. PubMed ID: 29588398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins.
    Barash JR; Arnon SS
    J Infect Dis; 2014 Jan; 209(2):183-91. PubMed ID: 24106296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic efficacy of equine botulism heptavalent antitoxin against all seven botulinum neurotoxins in symptomatic guinea pigs.
    Barker D; Gillum KT; Niemuth NA; Kodihalli S
    PLoS One; 2019; 14(9):e0222670. PubMed ID: 31527885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potency and stability of a trivalent, catalytically inactive vaccine against botulinum neurotoxin serotypes C, E and F (triCEF).
    Webb R; Wright PM; Brown JL; Skerry JC; Guernieri RL; Smith TJ; Stawicki C; Smith LA
    Toxicon; 2020 Mar; 176():67-76. PubMed ID: 32032587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.